A new NIH-funded study suggests that testosterone levels may play a significant role in the progression of glioblastoma, the most aggressive form of brain cancer, in men. The preclinical research found that men with lower levels of testosterone tended to have shorter survival times when diagnosed with glioblastoma compared to those with higher levels of the male sex hormone.
The findings, published in a peer-reviewed journal, highlight a potential link between androgens and brain tumor biology. The study's lead author noted that the results could lead to new treatment strategies, particularly for male patients with glioblastoma. The research was supported by the National Institutes of Health and conducted using animal models and human tissue samples.
This discovery is particularly relevant for companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP), which are developing therapies for central nervous system cancers. The study opens an interesting angle for considering androgen-based approaches in glioblastoma treatment, potentially complementing existing therapies.
Glioblastoma is a rapidly growing tumor that forms from star-shaped glial cells that support nerve cells. Despite advances in surgery, radiation, and chemotherapy, the prognosis remains poor, with a median survival of around 15 months. The new research suggests that testosterone levels could serve as a biomarker for prognosis or a target for intervention.
However, experts caution that the study is preclinical and further research is needed to confirm the findings in larger clinical trials. The mechanisms by which testosterone influences tumor growth are still under investigation. The study also raises questions about whether testosterone therapy could be beneficial for glioblastoma patients with low levels, though such treatments carry risks.
The study was funded by the NIH and conducted by researchers at multiple institutions. It adds to a growing body of evidence that sex hormones can influence cancer progression in both men and women. For glioblastoma, previous studies have shown that the disease is more common in men, and this new research may help explain why.
The findings were disseminated by BioMedWire, a specialized communications platform covering biotechnology and life sciences. BioMedWire is one of over 75 brands within the Dynamic Brand Portfolio @IBN, which offers a range of services including press release enhancement and social media distribution. The company is based in Austin, Texas, and can be reached at BioMedWire.com.
